Your browser doesn't support javascript.
loading
Case report: Disseminated herpes simplex virus 1 infection and hemophagocytic lymphohistiocytosis after immunomodulatory therapy in a patient with coronavirus disease 2019.
Mazzotta, Elvio; Fiorda Diaz, Juan; Echeverria-Villalobos, Marco; Eisinger, Gregory; Sprauer, Sarah; Singha, Arindam; Lyaker, Michael R.
Afiliación
  • Mazzotta E; Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Fiorda Diaz J; Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Echeverria-Villalobos M; Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Eisinger G; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine and Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Sprauer S; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine and Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Singha A; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine and Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Lyaker MR; Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Front Med (Lausanne) ; 9: 1053012, 2022.
Article en En | MEDLINE | ID: mdl-36479095
Corticosteroids and immunomodulatory therapies are widely used to treat patients with severe coronavirus disease 2019 (COVID-19). Janus kinase (JAK) inhibitors such as tofacitinib have been recently studied as adjuvants in the treatment of COVID-19. Although immunomodulatory therapies may be linked to decreased mortality rates in the acute phase, subsequent severe infectious complications may result from them. We describe a case of a multiorgan system failure secondary to disseminated primary herpes simplex virus 1 (HSV-1) infection and hemophagocytic lymphohistiocytosis (HLH) following treatment with tofacitinib and high-dose dexamethasone therapy for severe COVID-19. Early diagnosis and treatment of these life-threatening conditions may have a significant impact on COVID-19 patients' outcomes.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Screening_studies Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Screening_studies Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza